Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Biomaterials. 2018 May 26;176:71–83. doi: 10.1016/j.biomaterials.2018.05.041

Fig. 7. THR enhanced AAV8 transduction by decreasing AAV8 clearance in the blood.

Fig. 7

(A, B) The mice were immunized with the incubated complex of 2×1011 vg of AAV8/luc and 0.1 mM THR peptide via a retro-orbital injection. The luciferase expression was measured on days 2 and 7. (C) The blood was also collected from the retro-orbital plexus at various time points as shown after injection, and the viral titers were tested by qPCR. The data represents the average and SD from five mice. Asterisks indicate the statistical significance when compared to the AAV8-CBA-luc alone treatment group (*p < 0.05; **p < 0.01, ***p < 0.001).